Browsing Centre for Cell and Molecular Biology by Author "Rajan, P"
Now showing items 1-5 of 5
-
Developing and centralising a nurse-led local anaesthetic transperineal biopsy service during COVID.
Winters, DA; Mehmi, A; Odedra, A; Wilson, L; Ancheta, J; Buttleman, S; Allchorne, P; Rajan, P; Khan, S; Green, JSA (Wiley, 2023-05-31)INTRODUCTION: Transperineal (TP) biopsy has recently replaced the transrectal ultrasound (TRUS) approach as the ideal method of biopsy in the United Kingdom with growing trends to adopt. To minimise transmission of COVID-19 ... -
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.
Dinneen, E; Shaw, GL; Kealy, R; Alexandris, P; Finnegan, K; Chu, K; Haidar, N; Santos-Vidal, S; Kudahetti, S; Moore, CM (2022-11)OBJECTIVES: To test the feasibility of a randomised controlled trial (RCT) of aspirin and/or vitamin D3 in active surveillance (AS) low/favourable intermediate risk prostate cancer (PCa) patients with Prolaris® testing. ... -
Management of stage II seminoma: a contemporary UK perspective
Alifrangis, C; Nicol, DL; Shamash, J; Rajan, P (2022) -
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer
Davies, CR; Guo, T; Burke, E; Stankiewicz, E; Xu, L; Mao, X; Scandura, G; Rajan, P; Tipples, K; Alifrangis, C (Frontiers Media, 2023-01-16)Background: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired ... -
Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer
Atalar, K; Rajan, P (Nature Research, 2022-10-24)